Product nameAnti-TAB2 antibody
See all TAB2 primary antibodies
DescriptionRabbit polyclonal to TAB2
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Mouse, Human
Synthetic peptide within Human TAB2 aa 500-550. The exact sequence is proprietary. NP_055908.1
Database link: Q9NYJ8
- WB: HeLa, HEK-293T and NIH/3T3 whole cell lysate. IP: HeLa whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab264309 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 76 kDa.|
|IP||Use at 2-5 µg/mg of lysate.|
FunctionAdapter linking MAP3K7/TAK1 and TRAF6. Promotes MAP3K7 activation in the IL1 signaling pathway. The binding of 'Lys-63'-linked polyubiquitin chains to TAB2 promotes autophosphorylation of MAP3K7 at 'Thr-187'. Involved in heart development.
Tissue specificityWidely expressed. In the embryo, expressed in the ventricular trabeculae, endothelial cells of the conotruncal cushions of the outflow tract and in the endothelial cells lining the developing aortic valves.
Involvement in diseaseDefects in TAB2 are the cause of congenital heart disease non-syndromic type 2 (CHTD2) [MIM:612863]. It is a disease characterized by congenital developmental abnormalities involving structures of the heart. Clinical features include left ventricular outflow tract obstruction, subaortic stenosis, residual aortic regurgitation, atrial fibrillation, bicuspid aortic valve and aortic dilation. Note=A chromosomal aberration involving TAB2 has been found in a family with congenital heart disease. Translocation t(2;6)(q21;q25).
Sequence similaritiesContains 1 CUE domain.
Contains 1 RanBP2-type zinc finger.
modificationsUbiquitinated; following IL1 stimulation or TRAF6 overexpression. Ubiquitination involves RBCK1 leading to proteasomal degradation.
Cellular localizationMembrane. Cytoplasm > cytosol. Following IL1 stimulation, translocation occurs from the membrane to cytosol.
- Information by UniProt
- CHTD2 antibody
- FLJ21885 antibody
- KIAA0733 antibody
All lanes : Anti-TAB2 antibody (ab264309) at 0.1 µg/ml
Lane 1 : HeLa whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 5 µg
Lane 4 : HEK-293T whole cell lysate at 50 µg
Lane 5 : NIH/3T3 whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 76 kDa
Exposure time: 3 minutes
TAB2 was immunoprecipitated from 1mg of HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate with ab264309 at 3 µg/mg lysate. Western blot was performed from the immunoprecipitate using ab264309 at 1 µg/ml.
Lane 1: ab264309 IP in HeLa whole cell lysate.
Lane 2: Control IgG.
Exposure time: 30 secs.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab264309 has not yet been referenced specifically in any publications.